Summit Creek Advisors LLC Buys New Stake in LeMaitre Vascular, Inc. $LMAT
Summit Creek Advisors LLC acquired a new stake of 49,174 shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the second quarter, valued at approximately $4.72 million. Other hedge funds also adjusted their positions in the medical instruments supplier. The company recently reported its quarterly earnings, missing analyst estimates, and announced a quarterly dividend of $0.25 per share.
Bank of America Corp DE Increases Stock Holdings in LeMaitre Vascular, Inc. $LMAT
Bank of America Corp DE increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 39.0% in the first quarter, now owning 180,095 shares worth $19.66 million. Several other institutional investors also adjusted their positions in the medical instruments supplier. LeMaitre Vascular recently reported Q1 earnings that missed analyst estimates and declared a quarterly dividend of $0.25 per share.
Rice Hall James & Associates LLC Purchases Shares of 189,907 LeMaitre Vascular, Inc. $LMAT
Rice Hall James & Associates LLC recently acquired 189,907 shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the second quarter, totaling approximately $18.2 million and representing 0.83% of the company. Despite institutional ownership reaching 84.64%, LeMaitre Vascular missed quarterly earnings and revenue estimates, though revenue still grew by 9.6% year-over-year. The company declared a $0.25 quarterly dividend, and analysts currently hold an average "Hold" rating with a target price of $110.60.
Q2 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
This article analyzes the Q2 earnings of LeMaitre (NASDAQ:LMAT) and compares its performance with other companies in the surgical equipment & consumables - specialty sector. While the overall sector reported satisfactory Q2 results with revenues beating estimates, LeMaitre delivered the weakest performance against analyst estimates and saw its stock drop significantly. In contrast, Teleflex (NYSE:TFX) had the fastest revenue growth, and Intuitive Surgical (NASDAQ:ISRG) achieved the biggest analyst estimate beat.
LeMaitre Vascular (NasdaqGM:LMAT) Stock Forecast & Analyst Predictions
LeMaitre Vascular (LMAT) is forecast to grow earnings by 8.5% and revenue by 8.7% annually. Analysts have a price target of US$110, 35% above the current price, despite the stock being down 12% over the past year and recent earnings missing estimates. The company recently announced a quarterly dividend of US$0.25 and provided earnings guidance for upcoming quarters and full year 2026.
How Investors May Respond To LeMaitre Vascular (LMAT) Trimmed 2026 Outlook Despite Higher Q2 Sales
LeMaitre Vascular (LMAT) reported higher Q2 2026 sales and net income, but trimmed its full-year 2026 revenue outlook due to currency headwinds, Middle East export delays, and cardiac allograft supply constraints. This guidance reduction, despite growth, highlights operational risks and may lead some investors to adopt a more cautious view, though the company's long-term narrative projects significant revenue and earnings growth. The article advises investors to form their own verdict by exploring the company's financial health and other fair value estimates.
How Investors May Respond To LeMaitre Vascular (LMAT) Trimmed 2026 Outlook Despite Higher Q2 Sales
LeMaitre Vascular (LMAT) reported higher Q2 2026 sales and net income, but trimmed its full-year 2026 outlook due to currency headwinds, Middle East export delays, and cardiac allograft supply constraints. Despite these challenges, the company reinforced its growth narrative, though the revised guidance highlights operational risks. Investors should consider the updated forecast of $274.3-$278.3 million in sales and $2.84-$2.94 EPS for 2026, which represents a modest trim from prior targets.
LeMaitre Vascular remains a Buy despite 31% pullback; strong organic growth and record margins support outlook.
LeMaitre Vascular's stock experienced a 31% drop after missing Q2 2026 expectations due to currency issues, export blockages, and tissue shortages. However, the company demonstrates strong underlying demand with 10% organic sales growth and record-high margins, driven by its fastest-growing product, Artegraft. Despite the valuation reset, its 11% organic growth guidance, solid balance sheet, and expanding biologics portfolio make it a compelling buy, with a price target adjusted to $95-$100 for year-end 2027.
LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Navigating a 39% Potential Upside in the Healthcare Sector
LeMaitre Vascular, Inc. (LMAT), a healthcare sector player specializing in vascular surgery medical devices, shows a potential upside of 39.33% with an average target price of $113.13. Despite trading below its 50-day and 200-day moving averages, the company exhibits strong operational efficiency, a healthy free cash flow, and a positive outlook from analysts. Its diverse product portfolio and strategic market positioning make it an attractive investment for growth-seeking investors.
LeMaitre Vascular (LMAT) Has A Fresh Update, So Why Is It Drawing Attention?
LeMaitre Vascular (LMAT) recently released strong second-quarter 2026 results with increased sales and net income, alongside updated guidance and a reaffirmed cash dividend. Despite positive long-term shareholder returns, recent share price performance has been weak. The stock is considered undervalued by analysts, trading 31.4% below an estimated fair value of $118.75, primarily due to expectations of strong revenue growth and improved margins from its product pipeline.
Quantinno Capital Management LP Buys 18,204 Shares of LeMaitre Vascular, Inc. $LMAT
Quantinno Capital Management LP significantly increased its stake in LeMaitre Vascular, Inc. by 357.4%, acquiring 18,204 additional shares. This brings their total holding to 23,298 shares, valued at approximately $2.54 million. The news comes as LeMaitre Vascular faces mixed analyst sentiment due to missing Q2 revenue and earnings estimates, although it did report a 9.6% year-over-year revenue growth.
LeMaitre Vascular, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
LeMaitre Vascular, Inc. recently missed its statutory earnings estimates, causing its shares to drop by 21%. Despite the earnings miss, revenue remained in line with predictions, and analysts have largely maintained their price targets, though they slightly downgraded next year's EPS forecasts. The company is still expected to grow faster than the overall industry, with long-term prospects remaining positive according to analysts.
LeMaitre Vascular, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
LeMaitre Vascular (NASDAQ: LMAT) shares fell 21% after missing statutory earnings estimates, though revenues were in line with predictions. Analysts have since slightly downgraded their earnings per share forecasts for 2026, yet the consensus price target remained unchanged at US$114, implying that the valuation is not expected to be significantly impacted. The company is still projected to grow revenues faster than the broader industry.
31% Undervalued? LeMaitre Vascular (LMAT) After Earnings Guidance And Dividend Update
LeMaitre Vascular (LMAT) reported strong Q2 2026 results with increased sales and net income, affirming its quarterly dividend. While analysts view the stock as 31.4% undervalued with a fair value of $118.75 due to a strong product pipeline and pricing power, Simply Wall St's DCF model suggests it is overvalued at $81.45 compared to an estimated future cash flow value of $69.27. Investors are encouraged to review these differing valuations and consider the company's risks and opportunities.
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
LeMaitre Vascular, Inc. announced its participation in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, where management will hold investor meetings on August 11, 2026. The company specializes in providing devices, implants, and services for treating peripheral vascular disease, catering to vascular surgeons. Additional information about LeMaitre, including its contact details, is available on its website.
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
LeMaitre Vascular, Inc. announced its participation in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, scheduled for Tuesday, August 11, 2026. Management will hold investor meetings at this event. LeMaitre is a medical device company specializing in products for peripheral vascular disease.
LeMaitre management to meet investors at virtual Aug. 11 event
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that its management will participate in investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026. The event will be held in a virtual format. The company specializes in devices and services for peripheral vascular disease.
LeMaitre Vascular To Go Ex-Dividend On August 20th, 2026 With 0.25 USD Dividend Per Share
LeMaitre Vascular is scheduled to go ex-dividend on August 20th, 2026. The company will be distributing a dividend of $0.25 per share to its shareholders. Investors wishing to receive this dividend should ensure they own shares before the ex-dividend date.
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
LeMaitre Vascular, Inc. announced its participation in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 11, 2026, where management will hold investor meetings. The company, a provider of devices for peripheral vascular disease, aims to connect with investors regarding its business. This announcement follows recent financial results and earnings release notifications.
LeMaitre Vascular Down Over 22%, On Track for Largest Percent Decrease Since October 2008 -- Data Talk
LeMaitre Vascular's stock is down over 22% today, putting it on track for its largest single-day percentage decrease since October 2008. The company's stock price has also fallen below its 50-day and 200-day moving averages, signaling a potentially significant downward trend. This decline follows a period of outperformance compared to the broader S&P 500 index.
LeMaitre Vascular (NASDAQ:LMAT) Sets New 1-Year Low on Analyst Downgrade
LeMaitre Vascular (NASDAQ:LMAT) shares hit a new 52-week low after Wells Fargo downgraded its price target and maintained an equal-weight rating, amidst a broader shift in analyst sentiment to "Hold." The company's Q2 revenue and EPS, despite year-over-year growth, missed analyst expectations, leading to a lowered full-year 2026 outlook. Insider sales by CEO George W. Lemaitre and Trent G. Kamke also occurred in May, contributing to the negative sentiment around the stock.
LeMaitre Vascular, Inc. Stock 12‑Month Price Target Cut to $116.25, Implies 10% Upside
LeMaitre Vascular, Inc.'s average 12-month price target has been lowered from $118.75 to $116.25 by 8 analysts, suggesting a 10% upside from its Aug. 4 closing price. The consensus rating remains a "Buy" from 9 analysts, with 5 recommending Buy and 4 recommending Hold.
LeMaitre Vascular stock hits 52-week low at 79.38 USD
LeMaitre Vascular (LMAT) stock recently hit a 52-week low at $79.38, despite having a strong 1-year return of nearly 25% and being up over 31% year-to-date. The medical device maker is trading below its Fair Value estimate, with analysts setting price targets between $100 and $135, suggesting potential upside. The recent drop followed second-quarter earnings that, while showing year-over-year growth, missed Wall Street expectations, leading the company to revise its full-year growth outlook downward.
LeMaitre Vascular Down Over 22%, On Track for Largest Percent Decrease Since October 2008 -- Data Talk
LeMaitre Vascular Inc. (LMAT) experienced a significant drop of over 22%, trading at $82.06, which would mark its lowest close since January 2026. This decline puts the company on track for its largest percentage decrease since October 2008. The stock is down 30.1% from its all-time high in April 2026, despite being up 1.18% year-to-date.
LeMaitre Vascular (NASDAQ:LMAT) Price Target Cut to $94.00 by Analysts at Wells Fargo & Company
Wells Fargo & Company analysts have cut their price target for LeMaitre Vascular (NASDAQ:LMAT) to $94.00 from $104.00, maintaining an "equal weight" rating. This adjustment follows the company's recent earnings report where Q2 EPS of $0.74 missed the consensus estimate of $0.81, and revenue of $70.38 million fell short of expectations. The medical instruments supplier currently has a "Hold" rating from analysts with a consensus price target of $110.60, despite recent downgrades from other firms.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Announces $0.25 Quarterly Dividend
LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend of $0.25 per share, payable on September 3rd to shareholders of record on August 20th. This announcement comes despite the company missing analyst expectations for both Q2 revenue and EPS, and subsequently lowering its full-year 2026 guidance. LeMaitre Vascular has a history of consistently increasing its dividend, having done so for 14 consecutive years.
Royal Bank of Canada Sells 18,448 Shares of LeMaitre Vascular, Inc. $LMAT
Royal Bank of Canada reduced its stake in LeMaitre Vascular, Inc. (LMAT) by 6.3% in the first quarter, selling 18,448 shares but still retaining a significant holding of 272,654 shares valued at $29.8 million. This comes as LeMaitre Vascular reported Q2 earnings that missed analyst expectations for both revenue and EPS, and subsequently lowered its full-year 2026 guidance. Despite these financial setbacks, analysts maintain a "Moderate Buy" consensus with an average price target of $112.60, and the company declared a quarterly dividend of $0.25 per share.
LeMaitre Vascular earnings on deck as margin gains test continues
LeMaitre Vascular (LMAT) is set to report its second-quarter earnings, with investors closely watching for margin expansion and profit growth. Analysts expect earnings of $0.81 per share on revenue of $71.5 million. The key focus will be on the company's ability to achieve its guided 500 basis points of operating margin expansion and whether management will raise full-year guidance for a second time, reinforcing confidence in its growth strategy.
LeMaitre Vascular Q2 Earnings Call Highlights
LeMaitre Vascular (NASDAQ: LMAT) reported strong Q2 2026 results with 10% organic revenue growth and record operating income, driven by Artegraft sales. However, the company missed sales guidance due to foreign exchange pressures, Middle East export disruptions, and cardiac allograft supply constraints, leading to a modest reduction in its 2026 outlook. LeMaitre Vascular plans continued investment in Artegraft's international expansion and distribution infrastructure.
LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag Estimates
LeMaitre Vascular (LMAT) reported Q2 earnings of $0.74 per share, falling short of the Zacks Consensus Estimate of $0.81, though it was an increase from $0.60 a year ago. The company's revenues of $70.38 million also missed expectations, despite being higher than the $64.23 million from the prior year. Despite underperforming estimates this quarter, LMAT shares have risen by 27.8% year-to-date, surpassing the S&P 500's 11% gain.
LeMaitre Vascular (NASDAQ:LMAT) Issues Q3 2026 Earnings Guidance
LeMaitre Vascular (NASDAQ:LMAT) has lowered its third-quarter 2026 earnings guidance, projecting EPS of $0.660–$0.710 and revenue of $66.3–$68.3 million, both below analyst consensus. The company also updated its full-year 2026 EPS guidance to $2.840–$2.940. Despite the lowered outlook, analyst sentiment remains "Moderate Buy" with an average price target of $112.60, though several analysts have recently downgraded the stock.
Earnings call transcript: LeMaitre Vascular slips on Q2 2026 miss, cuts outlook
LeMaitre Vascular reported a Q2 2026 earnings and revenue miss, leading to a significant after-hours stock drop. Despite strong year-over-year growth and margin expansion, the company cut its full-year organic revenue growth outlook due to foreign exchange pressures, Middle East shipping delays, and cardiac allograft supply limits. Management highlighted Artegraft as a key growth driver, with continued investment in international expansion and new product sizes.
LeMaitre Vascular (NASDAQ:LMAT) Updates FY 2026 Earnings Guidance
LeMaitre Vascular (NASDAQ:LMAT) has updated its FY 2026 earnings guidance, lowering its EPS outlook to $2.84-$2.94 and revenue guidance to $274.3-$278.3 million, both below analyst consensus. Despite this, the company's Q3 2026 EPS guidance was set at $0.66-$0.71, and its previous quarterly earnings beat estimates while revenue grew 11.1% year-over-year. Insider selling of approximately $5.9 million in shares has occurred over the last three months, though analyst sentiment remains moderately positive with a "Moderate Buy" rating.
LeMaitre says Artegraft is now approved in 56 countries
LeMaitre (NASDAQ: LMAT) reported strong Q2 2026 financial results with net sales up 10% year-over-year to $70.4 million and diluted EPS up 23% to $0.74. A key growth driver was Artegraft, whose sales increased by 34%, now representing 21% of total sales and approved in 56 countries. The company also declared a quarterly dividend of $0.25 per share and affirmed its full-year 2026 guidance for sales and EPS.
LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Exploring a 14.61% Potential Upside in the Healthcare Sector
LeMaitre Vascular, Inc. (LMAT) is a significant player in the healthcare sector, specifically in medical instruments for vascular surgery, with a market capitalization of $2.37 billion. The company shows strong financial health with 11.20% revenue growth, a 16.55% return on equity, and a forward P/E of 31.83. Analysts view LMAT favorably, with an average target price suggesting a 14.61% potential upside, making it an attractive prospect for growth-oriented investors despite short-term overbought signals.
LeMaitre Vascular earnings on deck as margin gains test continues
LeMaitre Vascular is set to announce its second-quarter earnings, with investors closely watching its ability to maintain significant margin expansion and accelerate profit growth. Analysts anticipate earnings of $0.81 per share on revenue of $71.5 million, reflecting substantial year-over-year growth. The company's premium valuation is supported by strong gross margins and double-digit revenue growth, as it specializes in devices for peripheral vascular disease.
LeMaitre Q2 2026 Financial Results
LeMaitre Vascular, Inc. reported strong Q2 2026 financial results with sales up 10% to $70.4 million and EPS up 23% to $0.74, driven by a 34% increase in Artegraft sales and operational efficiencies. The company announced a quarterly dividend of $0.25/share and provided optimistic guidance for Q3 and Q4 2026, projecting continued growth in sales, gross margin, operating income, and EPS. LeMaitre highlighted its strategic focus on international Artegraft launch and significant cash reserves for future optionality.
LeMaitre Q2 2026 Financial Results
LeMaitre Vascular, Inc. (Nasdaq: LMAT) reported strong Q2 2026 financial results, with sales reaching $70.4 million, a 10% increase year-over-year, and EPS of $0.74, up 23%. The company highlighted significant growth in Artegraft sales and its international expansion efforts, while also providing optimistic guidance for Q3, Q4, and the full year 2026. A quarterly dividend of $0.25/share was declared, and the company noted its substantial cash position for strategic optionality.
LeMaitre: Q2 Earnings Snapshot
LeMaitre Vascular Inc. (LMAT) reported a second-quarter profit of $17.1 million, or 74 cents per share, on revenue of $70.4 million. The medical device maker anticipates revenue for the current quarter to be between $66.3 million and $68.3 million, with full-year earnings projected at $2.84 to $2.94 per share and revenue from $274.3 million to $278.3 million.
LeMaitre Vascular, Inc. $LMAT Shares Sold by Segall Bryant & Hamill LLC
Segall Bryant & Hamill LLC reduced its stake in LeMaitre Vascular, Inc. (LMAT) by 34.9% in the first quarter, selling 27,990 shares and retaining 52,252 shares valued at approximately $5.7 million. The medical instruments supplier reported strong Q1 earnings, beating estimates with $0.68 EPS and an 11.1% revenue increase year-over-year. Despite a "Moderate Buy" consensus from analysts, company insiders have sold a significant number of shares recently.
LeMaitre Vascular (LMAT) Holds A 15% Undervalued View, Is The Stock Fully Priced?
LeMaitre Vascular (LMAT) closed at $101.32 on July 29, 2026, and is considered 15% undervalued with a fair value of $118.75 based on analyst forecasts and a strong product pipeline. However, its P/E ratio of 37.1x screens as expensive against the market and industry, despite being cheaper than closest peers, raising questions about whether this reflects a quality premium or a valuation risk. Investors are advised to consider potential challenges like slower organic unit growth and pressure on pricing power.
Renaissance Technologies LLC Has $15.12 Million Position in LeMaitre Vascular, Inc. $LMAT
Renaissance Technologies LLC decreased its stake in LeMaitre Vascular, Inc. by 23.3% during the first quarter, now holding shares worth approximately $15.12 million. Despite this reduction, institutional investors collectively own 84.64% of the company, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $112.60. The company recently surpassed earnings expectations, reporting an EPS of $0.68 against an anticipated $0.66, with revenue increasing 11.1% year-over-year to $66.55 million.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Rating of "Moderate Buy" by Brokerages
LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received an average "Moderate Buy" rating from brokerages, with an average 12-month price target of $112.60. The company recently surpassed quarterly EPS expectations and saw an 11.1% revenue increase. Despite insider stock sales totaling approximately $5.9 million, institutional investors and hedge funds hold a significant 84.64% stake in the company.
Precision Trading with Lemaitre Vascular Inc. (LMAT) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Lemaitre Vascular Inc. (LMAT) focusing on precision trading strategies and risk zones. It highlights near-term strong sentiment, mid-term neutrality, and long-term positive bias, along with specific entry, target, and stop-loss levels for different trading strategies (Position, Momentum Breakout, and Risk Hedging). The analysis also includes multi-timeframe signal insights and AI-generated signals for support and resistance.
Sei Investments Co. Boosts Stock Holdings in LeMaitre Vascular, Inc. $LMAT
Sei Investments Co. increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 30.7% in the first quarter, now holding 136,674 shares valued at $14.92 million. Other
LeMaitre Vascular Inc (LMAT) Institutional Confidence
LeMaitre Vascular Inc (LMAT) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. This score reflects a quarter-over-quarter increase of 8.41% in institutional shareholding proportion, which currently stands at 102.98%. ETHSX is the largest institutional shareholder, holding 1.04% of outstanding shares with a significant increase in their holdings.
LeMaitre Vascular Inc (LMAT) Financial Health: Profitability & Balance Sheet Analysis
LeMaitre Vascular Inc (LMAT) has a robust financial status with a current financial score of 9.04, ranking 11th in the Healthcare Equipment & Supplies industry. The company demonstrated high operating efficiency with a 11.16% year-over-year increase in quarterly revenue to $66.55M and a 42.39% year-over-year increase in net profit. Key financial metrics related to Cash and Cash Equivalents, Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns are awaiting detailed disclosure.
LeMaitre Vascular (LMAT) insider Bridget Ross files to sell 4,322 shares
LeMaitre Vascular insider Bridget A. Ross has filed to sell 4,322 shares of common stock, valued at $449,241.48, through a Form 144. The sale is expected on July 29, 2026, and relates to a stock option exercise. Ross previously sold 5,044 shares for $560,366.40 on May 7, 2026.
Ranger Investment Management L.P. Lowers Stake in LeMaitre Vascular, Inc. $LMAT
Ranger Investment Management L.P. significantly reduced its stake in LeMaitre Vascular, Inc. by 36.8% during the first quarter, selling 138,672 shares. Despite this reduction, other institutional investors like Annex Advisory Services LLC, Tudor Investment Corp ET AL, Wakefield Asset Management LLLP, Kennedy Capital Management LLC, and Vanguard Group Inc. increased their holdings in the medical instruments supplier. The article also notes recent insider selling by Trent G. Kamke and CEO George W. Lemaitre, alongside updated analyst ratings and financial performance details for LeMaitre Vascular.
LeMaitre Vascular, Inc. Revenue Breakdown – FWB:LHU
LeMaitre Vascular, Inc. (FWB:LHU) generated 212.52 million EUR last year, primarily from its Medical Devices and Human Tissue Cryopreservation segment. The United States was the company's largest regional contributor, accounting for 120.53 million EUR of the revenue. This data highlights the key revenue drivers for the medical technology company.
